Premium
Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib
Author(s) -
Yeganeh M.,
Finn R. S.,
Saab S.
Publication year - 2009
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2009.02860.x
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , liver transplantation , transplantation , gastroenterology , metastasis , incidence (geometry) , biopsy , carcinoma , tyrosine kinase inhibitor , oncology , surgery , cancer , physics , optics
Hepatocellular carcinoma (HCC) remains a significant disease worldwide and its incidence is expected to increase. In selected patients, liver transplantation offers a 5‐year patient survival between 48% and 75%. However, HCC recurrence occurs in approximately 20% of transplant recipients. No therapy has proven efficacious in decreasing the risk of recurrence after transplantation. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced HCC that have no history of liver transplantation. We report complete remission of HCC in a 54‐year‐old man who developed biopsy‐proven lung metastasis after liver transplantation treated with sorafenib.